SNY

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Retrieved on: 
星期五, 四月 5, 2024
Research, Other Health, Pharmaceutical, Vacation, Other Travel, Infectious Diseases, Destinations, Travel, Clinical Trials, Science, Biotechnology, Health, Other Science, SNY, Rabies, Risk, SAN, Death, Dog, Post-exposure prophylaxis, Licensure, Fox, Vaccine

Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK, an inactivated rabies vaccine indicated for pre-exposure and post-exposure prophylaxis of rabies in all age groups.1

Key Points: 
  • Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK, an inactivated rabies vaccine indicated for pre-exposure and post-exposure prophylaxis of rabies in all age groups.1
    This launch is based on extensive clinical data from over 13,000 individuals.1 Sanofi Inactivated Rabies Vaccine has been approved and widely used in more than 80 countries.2 It is estimated that between 41 and 70 million individuals have received the vaccine since its first licensure in May 1985, in France.2
    Rabies is nearly always fatal once symptoms appear, but can be preventable with vaccination3
    Each year, an estimated 59,000 people worldwide die from rabies.4 That’s one person every nine minutes of every day3, with approximately 95% of deaths occurring in Asia and Africa.3,4,5 Individuals travelling to these countries should be aware of the risk of rabies and take the appropriate precautionary measures.
  • Rebecca Catterick, UK and Ireland Sanofi Vaccines General Manager, said:
    “Rabies is a fatal, travel-related vaccine-preventable disease.
  • The availability of Verorab® in the UK provides an effective immunisation option for those travelling to high-risk countries, as well as a treatment for post-rabies exposure.”
    Joanna Lowry, Specialist Travel Nurse & Educator, said:
    “I am always surprised by the number of British travellers I meet who are unaware of the risk of rabies.
  • Increasing awareness and sharing education on preventative measures is crucial to help reduce the possibility of this devastating disease.”
    Rabies is primarily transmitted by the bite, scratch, or lick of a rabid animal, 99% of which are by dogs, but can also be other wildlife, such as foxes or bats.6

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting

Retrieved on: 
星期二, 二月 20, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, SNY, SAN, Ulcerative colitis, Crohn's disease, TEVA, Inflammation, European, Teva, Teva Pharmaceuticals, Asthma, Gastrointestinal tract, Safety, UC, Immunoglobulin G, Inflammatory bowel disease, Patient, Fibrosis, TL1A, IBD, Medication, TNF, ECCO, Pharmaceutical industry

“These results from the first-in-human trials of anti-TL1A (TEV-’574) are exciting because they show that it effectively engages with the TL1A target, supports its safety profile and is well-tolerated.

Key Points: 
  • “These results from the first-in-human trials of anti-TL1A (TEV-’574) are exciting because they show that it effectively engages with the TL1A target, supports its safety profile and is well-tolerated.
  • “We are currently investigating the efficacy and safety of anti-TL1A (TEV-’574) in IBD through the RELIEVE UCCD Phase 2 trial, which features an innovative and efficient basket study design allowing the inclusion of patients with either type of IBD (ulcerative colitis and Crohn’s disease).
  • Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement, and Sanofi will lead the development of the Phase 3 program.
  • Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world.

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Retrieved on: 
星期一, 一月 22, 2024
Brain, Type 2, LMD, Legislation, Incidence, C-peptide, Cancer, SNY, Panobinostat, GBM, Letter, Trial of the century, Neoplasm, CFO, Diffusion, Cell proliferation, Central nervous system, Apoptosis, Type 1 diabetes, Patent, Breast, Metabolism, Diffuse intrinsic pontine glioma, Type 2 diabetes, Survival, DIPG, MGMT, Patient, Toxicology, Glioblastoma, Tolimidone, Pfizer, Insulin, OXPHOS, Plasma, Oxidative phosphorylation, FDA, Progression-free survival, Convection, Columbia University, Type 1, Cerebrospinal fluid, DMG, Pharmaceutical industry

In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.

Key Points: 
  • In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.
  • Tolimidone is an activator of lyn kinase which has been shown to play a significant role in cell proliferation, differentiation, apoptosis, migration and metabolism.
  • We expect to report data from the in vivo LMD efficacy model by the end of the first quarter of 2024.
  • Certain statements in this shareholder letter may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States.

Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target

Retrieved on: 
星期三, 一月 3, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Research, Patient, XE, CRISPR, Therapy, SNY, Pharmaceutical industry

Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that Sanofi (NASDAQ: SNY) has exercised its option for a second target as part of the companies' research collaboration to develop in vivo CRISPR-based therapeutics.

Key Points: 
  • Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that Sanofi (NASDAQ: SNY) has exercised its option for a second target as part of the companies' research collaboration to develop in vivo CRISPR-based therapeutics.
  • “We are pleased to advance our ongoing in vivo collaboration with Sanofi to address a second therapeutic target based on our progress to date working on potentially curative genetic medicines,” said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe.
  • Scribe will receive a milestone payment associated with the second target nomination and be eligible to receive additional development and commercial milestones upon advancement of the program.
  • Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology indications in 2022, followed by an expansion of the collaboration in 2023 to advance in vivo medicines for genomic diseases.

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

Retrieved on: 
星期二, 十二月 19, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Clinical Trials, Partnership, Euronext Paris, Doctor of Philosophy, IPH, DVM, Cancer, Patient, SNY, IPHA, Exercise, Senior, Vaccine

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate’s ANKET® (Antibody-based NK Cell Engager Therapeutics) platform pursuant to the terms of the research collaboration and license agreement signed in December 2022 .

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate’s ANKET® (Antibody-based NK Cell Engager Therapeutics) platform pursuant to the terms of the research collaboration and license agreement signed in December 2022 .
  • Following a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization.
  • Innate Pharma is eligible for up to €1.35bn total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.
  • Valeria Fantin, Ph.D., Global Head of Oncology Research at Sanofi, states: “Sanofi is pleased with our collaboration with Innate and continues to be excited at the potential of investigational NK Cell Engagers.

GoodRx Announces New Way for Consumers to Access Sanofi’s Lantus for $35 at Over 70,000 Pharmacies Nationwide

Retrieved on: 
星期四, 十月 19, 2023
Women, Retail, Men, Pharmaceutical, Insurance, Software, Family, Internet, Consumer, Professional Services, Technology, Medical Supplies, General Health, Diabetes, Health, Apps, Applications, Health Technology, Specialty, Health Insurance, Patient, American Diabetes Association, Walmart, News, SNY, Pharmacy, CVS, Insulin, Pharmaceutical industry, Insulin glargine, Walgreens, Sanofi, GoodRx

Sanofi is taking action and providing Americans who need insulin with the ability to access Lantus in an easy and affordable way, regardless of insurance status.

Key Points: 
  • Sanofi is taking action and providing Americans who need insulin with the ability to access Lantus in an easy and affordable way, regardless of insurance status.
  • We’re proud to collaborate with them on this initiative,” said Dorothy Gemmell, Chief Commercial Officer at GoodRx.
  • Patients can visit GoodRx.com/lantus to access the $35 price coupon, which can be redeemed at any pharmacy that accepts GoodRx, including CVS, Walgreens, and Walmart.
  • This complements other savings programs already offered by Sanofi, including offering Lantus for $35 per month to people without insurance.

Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

Retrieved on: 
星期三, 十月 4, 2023
Biotechnology, Pharmaceutical, Health, Teva Pharmaceuticals, TEVA, Teva, Crohn's disease, Diarrhea, IBD, Disease, TEV, Weight loss, Inflammation, Abdominal pain, Ulcerative colitis, Science, Pivot, Inflammatory bowel disease, SAN, TASE, SNY, GI, NYSE, Fatigue, Pharmaceutical industry, Fine chemical, Sanofi

Inflammatory bowel disease (IBD) is the term for two conditions -- Crohn’s disease and ulcerative colitis – characterized by chronic inflammation of the gastrointestinal (GI) tract. Prolonged inflammation results in damage to the GI tract. The common symptoms for both conditions are persistent diarrhea, rectal bleeding, abdominal pain, fatigue, and weight loss. An estimated ~10 million people worldwide live with IBD.

Key Points: 
  • Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today a collaboration to co-develop and co-commercialize asset TEV ‘574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.
  • This collaboration further validates the great science that Teva has to offer with our internally developed anti-TL1A.
  • Inflammatory bowel disease (IBD) is the term for two conditions -- Crohn’s disease and ulcerative colitis – characterized by chronic inflammation of the gastrointestinal (GI) tract.
  • Teva will hold an investor call and live webcast today (Wednesday, October 4, 2023) at 8:00 a.m.

Nexstar Media Group Enters Into Multi-Year Employment Agreement Extensions With Sean Compton, President, Networks, and Dana Zimmer, President, Distribution and Strategy

Retrieved on: 
星期一, 七月 17, 2023
TV and Radio, Media, Advertising, Communications, Online, General Entertainment, Mobile Entertainment, Entertainment, Network, Premiere Networks, Comcast, Executive, Tribune Media, Employment, IHeartMedia, Media Group, Ron Wilson (Clear Channel radio host), Tribune, Fox, The CW, Clear, CBS, Marketing, NBC, Discovery, Inc., Rewind TV, Nexstar, Acquisition, SNY, NewsNation, WGN (AM), ABC, WGN America, NBCUniversal, Growth, YES Network, Hill, Radio, Nexstar Media Group, Antenna TV, Television, Content, Distribution

Nexstar Media Group, Inc. (the “Company”) (Nasdaq: NXST), announced today that it extended the employment agreements of Sean Compton, President, Networks, and Dana Zimmer, President, Distribution and Strategy.

Key Points: 
  • Nexstar Media Group, Inc. (the “Company”) (Nasdaq: NXST), announced today that it extended the employment agreements of Sean Compton, President, Networks, and Dana Zimmer, President, Distribution and Strategy.
  • Perry Sook commented, “We are thrilled to extend the employment agreements of Sean and Dana whose leadership has helped drive our growth and shareholder returns.
  • Our strong industry position and positive growth prospects reflect Sean and Dana’s leadership and key contributions alongside the Nexstar Nation team.
  • Prior to joining Nexstar, Ms. Zimmer was President of Distribution and Marketing for Tribune Media Company from 2013 to 2019.

Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi

Retrieved on: 
星期四, 五月 18, 2023
Government, SNY, Federal Circuit Court, Research, Patient, Patent, Regeneron Pharmaceuticals, Judge, Supreme court, Sanofi, Amgen

Decision unanimously affirms the United States Federal Circuit Court's opinion that Amgen's asserted U.S. PCSK9 patent claims are invalid

Key Points: 
  • Decision unanimously affirms the United States Federal Circuit Court's opinion that Amgen's asserted U.S. PCSK9 patent claims are invalid
    BRIDGEWATER, N.J., May 18, 2023 /PRNewswire/ -- Sanofi (NASDAQ: SNY) is pleased with the United States Supreme Court's ruling in Amgen v. Sanofi et.
  • The decision unanimously affirms the United States Federal Circuit Court's opinion that is favorable to Sanofi and Regeneron.
  • This ruling reinforces our longstanding belief that Amgen's asserted patent claims are invalid and represents an unequivocal win for America's innovation economy, its scientists, and researchers.
  • We thank the Justices and the many groups, individuals and the U.S. government who supported our defense of scientific innovation.

Sanofi Announces Launch of AVAXIM® Junior in the UK for Active Immunisation Against Infection Caused by the Hepatitis A Virus in Children Aged 12 Months to 15 Years

Retrieved on: 
星期一, 四月 24, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Infection, Hepatitis, Vaccination, Parent, Developed country, SAN, Water, Ageing, SNY, Hepatitis A, Incidence, Disease, Vaccine, Sanofi

Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of AVAXIM® Junior in the UK, an inactive hepatitis A vaccine indicated for use in children aged 12 months to 15 years inclusive to prevent infection caused by the hepatitis A virus.1 The vaccination schedule consists of two vaccine doses injected by the intramuscular route 6 months to 36 months apart but can be given up to 7 years apart.1

Key Points: 
  • Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of AVAXIM® Junior in the UK, an inactive hepatitis A vaccine indicated for use in children aged 12 months to 15 years inclusive to prevent infection caused by the hepatitis A virus.1 The vaccination schedule consists of two vaccine doses injected by the intramuscular route 6 months to 36 months apart but can be given up to 7 years apart.1
    This launch was based on data from 20 clinical studies in 14 countries across Europe, the Middle East, Asia and the Americas, involving more than 6,200 children aged 12 months to 15 years who have received at least one dose of the vaccine in the context of a clinical trial.2 The data show that AVAXIM Junior is effective in inducing a protective antibody response within two weeks in over 95% of individuals, and in nearly 100% before the booster dose administered six months after the first dose.3
    Rebecca Catterick, UK and Ireland Sanofi Vaccines General Manager, said:
    “Hepatitis A is one of the most prevalent travel-related vaccine-preventable diseases, so the availability of effective options like AVAXIM Junior will offer parents peace of mind knowing that they can help protect their children when travelling to high-risk areas.”
    Hepatitis A is one of the most common vaccine-preventable, viral infections worldwide
    Hepatitis A, caused by the hepatitis A virus, is primarily transmitted through contaminated food and water or by direct contact with an infectious person.4 Incidence of the disease is closely related to socio-economic conditions, so it is most prevalent in developing countries with poor sanitary conditions and hygiene practices.4,5 It is the most common form of viral hepatitis6 and the third most common vaccine-preventable infection among travelers.7